Pancreatic Cancer Research

Clinical trialObservationalRecruiting

Use of Ctdna in Patients With Gastrointestinal Tract Tumors

Prospective Single-center Study About the Use of Ctdna in the Management of Patients With Tumors of the Gastrointestinal Tract

Outcome
Ongoing
Phase
Observational
Status
Recruiting
Study type
Observational
Start
1 November 2023
Expected end
1 November 2028
Enrollment
100 participants
Sites
1
Primary outcomes
mOS
Sponsor type
Academic / other
Results posted
No
Last update
2 September 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study will evaluate the use of ctDNA in the clinical management of patients with tumors of the gastrointestinal tract.

Detailed description public domain (ClinicalTrials.gov)

This is a a prospective observational single-center study; it is a spontaneous study, not sponsored by pharmaceutical companies, and does not involve the use of experimental drugs. The study involves a collection of data, carried out while protecting the anonymity and personal information of individual patients suffering from neoplasms of the gastrointestinal tract, the execution of peripheral blood samples and the collection of faecal material at pre-determined times -points. Circulating biomarkers (as ctDNA) will be evaluated in these samples, in order to optimize both the diagnostic and therapeutic processes of patients with tumors of the gastrointestinal tract.